CEPI

The next pandemic could begin anywhere, at any moment. And the risk of a deadly outbreak is only rising.

But it doesn’t have to be that way.

CEPI 3.0 is our plan to move the world from reactive response to proactive protection

Very welcome news: WHO’s Technical Advisory Group on Candidate Vaccines Prioritisation has recommended that two CEPI-funded vaccine candidates be evaluated in the Tumaini Phase 2/3 clinical trial in the Democratic Republic of the Congo. This takes us a step closer to safe and effective Bundibugyo-specific vaccines that could help save lives, bring the current outbreak under control and strengthen preparedness for the future.

Thanks to the commitment of our partners at the @UniofOxford, @SerumInstIndia and @moderna_tx, these promising candidates have progressed from concept to clinical trials at pace. CEPI is working closely with the developers, Tumaini trial partners and national authorities to get these vaccines into Tumaini as quickly as possible.

who.int/news/item/04-1…

"Now we’ll have the [mRNA] development capacity together with the production capacity. That makes a lot of difference in the event of pandemics.” - Dr Patrícia Neves, Head of RNA product development at Fiocruz Bio-Manguinhos.

Brazil has produced vaccines for 50 years, but when the COVID-19 pandemic hit, it couldn’t make mRNA vaccines of its own. Now Brazil’s Fiocruz Bio-Manguinhos vaccine institute is about to change that, with the first Brazilian patented mRNA vaccine platform starting human trials in 2027.

CEPI spoke to Dr Patrícia Neves, who is leading the CEPI-supported project, about what that means for Brazil and Latin America, as well as for other countries and regions hoping to learn from it.
@fiocruz
Read in full ➡️ cepi.net/innovations-fo…

A lot has happened in the world of epidemic and pandemic preparedness this October - check out CEPI's newsletter to catch up ⬇️

From the first participants vaccinated in a pivotal Phase 2/3 trial of Bundibugyo virus vaccine candidates to new partnerships strengthening regional outbreak readiness and the UN’s adoption of the Political Declaration on Pandemic Prevention, Preparedness and Response – discover what's been happening across the field.

linkedin.com/pulse/pivotal-…

When an outbreak strikes, clinical trials need to be ready to start quickly. That means building capacity before a crisis, not scrambling to put it in place once one begins.

That’s exactly what @AfricaCDC's hub-and-spoke clinical trial model aims to do: connect experienced research hubs with a network of sites closer to outbreak-prone areas, keeping them warm, connected and ready to generate clinical evidence when an outbreak strikes.

At the hub-and-spoke launch event in Accra on 22 October, convened by Africa CDC, the African Medicines Agency (AMA), WHO AFRO and CEPI, CEPI announced up to US$8.2 million in additional funding to support implementation of the model in West Africa.

The funding will support the International Vaccine Institute (IVI) and MRC Unit The Gambia at LSHTM (MRCG), the Technical Coordinating Partners leading CEPI’s Research Preparedness Program in the region.

The work closely aligns with CEPI’s Research Preparedness Program, also formally launched at the Accra event, which aims to strengthen clinical trial readiness in regions at risk of epidemics and pandemics and also supports CEPI’s 100 Days Mission—a goal to develop safe and effective vaccines within 100 days of identifying a new pandemic threat.

More here ➡️ cepi.net/strengthening-…